Overview of Transgene’s Liquidity Contract
Transgene has entrusted its liquidity management to Natixis Oddo BHF SCA, ensuring effective handling of its financial resources. As of June 30, 2025, key highlights from this arrangement reveal significant activity in both shares and capital.
Resources Managed through the Liquidity Account
Currently, the liquidity account under management is notable for holding:
- 327,750 shares
- €112,376
These resources play a crucial role in supporting Transgene's strategic operations and market activities.
Half-Year Performance in 2025
In the first half of 2025, the liquidity management saw considerable trading activity with a total of:
- Purchases: 249,004 shares valued at €180,297 across 769 market transactions.
- Sales: 280,915 shares for €212,020 accomplished in 967 market transactions.
This trading volume demonstrates the effectiveness of the liquidity strategy implemented by Natixis Oddo BHF SCA.
Comparative Analysis of Managed Resources
To understand the progression within the liquidity account, it's important to compare current figures with past data:
- End of 2024: 359,661 shares and €80,653.30 were managed.
- Transfer to Natixis Oddo BHF SCA (January 2, 2020): Resources included 164,183 shares and €246,158.
- Initial Setup in 2016: The liquidity program commenced with €500,000 in resources.
This historical perspective indicates that there have been fluctuations in both share numbers and capital as Transgene navigates through market conditions.
Importance of Effective Liquidity Management
Effective liquidity management is vital for any company, particularly for Transgene. By engaging Natixis Oddo BHF SCA, Transgene demonstrates its commitment to maintaining healthy market activity and ensuring that it has the necessary resources available for operational flexibility.
The management of shares and liquidity not only reflects on the current financial health but also supports strategic objectives and growth ambitions.
Future Prospects
As the market continues to evolve, Transgene’s strategic partnership with Natixis Oddo BHF SCA will likely adapt to these changes, ensuring calculated responses to market dynamics. Stakeholders can expect ongoing adjustments in the liquidity strategy as they work to optimize resources effectively.
Contact Information for Inquiries
For further information regarding the liquidity management and any associated inquiries, please reach out to:
Transgene
Lucie Larguier
Chief Financial Officer
+33 (0)3 88 27 91 00
investorrelations@transgene.fr
Frequently Asked Questions
What is the purpose of the liquidity contract with Natixis Oddo BHF?
The liquidity contract facilitates efficient management of Transgene’s shares and financial resources to enhance market activity.
How many shares were managed as of June 30, 2025?
As of that date, 327,750 shares were managed through the liquidity account.
What were the total purchases in the first half of 2025?
Total purchases amounted to 249,004 shares, valued at €180,297.
What comparisons can be made with previous years?
Comparative analysis shows variations in the management resources, with 359,661 shares and €80,653.30 managed at the end of 2024.
Who is the contact person for investor relations at Transgene?
Lucie Larguier, the Chief Financial Officer, is the point of contact for investor relations.
